

CITATION REPORT

List of articles citing

Monoclonal antibody pharmacokinetics and pharmacodynam

DOI: 10.1038/clpt.2008.170

Clinical Pharmacology and Therapeutics, 2008, 84, 548-58.

Source: <https://exaly.com/paper-pdf/43642124/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
796	Clinical pharmacology in the era of biotherapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 84, 533-6	6.1	5
795	Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor. 2009 , 102, 69-75		6
794	[Pharmacokinetics (PK) of mAbs]. 2009 , 25, 1057-62		9
793	Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. <i>MAbs</i> , 2009 , 1, 339-47	6.6	75
792	Immunotoxicity of monoclonal antibodies. <i>MAbs</i> , 2009 , 1, 104-11	6.6	96
791	Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers. 2009 , 53, 5055-9		12
790	Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. 2009 , 36, 341-51		40
789	Novel strategies for controlling <i>Streptococcus pyogenes</i> infection and associated diseases: from potential peptide vaccines to antibody immunotherapy. 2009 , 87, 391-9		12
788	Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. 2009 , 5, 803-12		81
787	The role of vascular endothelial growth factor genetic variability in cancer. 2009 , 15, 5297-302		66
786	Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. 2009 , 103, 77-115		122
785	Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. 2009 , 1, 1375-88		70
784	Interspecies scaling of therapeutic monoclonal antibodies: initial look. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 1382-402	2.9	106
783	Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 1056-70	2.9	70
782	Site-specific polysialylation of an antitumor single-chain Fv fragment. 2009 , 20, 924-31		48
781	Prediction of exposure-response relationships to support first-in-human study design. 2010 , 12, 750-8		34
780	Target-mediated drug disposition model for drugs that bind to more than one target. 2010 , 37, 323-46		39

779	Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents. 2010 , 128, 82-90		10
778	Prediction of therapeutic index of antibody-based therapeutics: mathematical modeling approaches. 330-343		
777	Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice. 2010 , 334, 327-32		13
776	Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. 2010 , 220, 71-6		51
775	Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 792-802	2.9	24
774	The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. 2010 , 333, 2-13		82
773	Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. 2010 , 285, 40135-47		82
772	Therapeutic monoclonal antibody concentration monitoring: free or total?. 2010 , 2, 1125-40		69
771	Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts. <i>MABs</i> , 2010 , 2, 67-72	6.6	15
770	Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. <i>MABs</i> , 2010 , 2, 576-88	6.6	72
769	A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12R α and IL-23-IL-23R. <i>MABs</i> , 2010 , 2, 539-49	6.6	12
768	Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor- α antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 600-5	4	94
767	Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. 2010 , 4, 355-66		227
766	Population pharmacokinetics of therapeutic monoclonal antibodies. 2010 , 49, 633-59		332
765	Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. 2010 , 49, 729-40		53
764	Effects of charge on antibody tissue distribution and pharmacokinetics. 2010 , 21, 2153-63		258
763	Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 117-27	5.4	32
762	Quantitative structure-pharmacokinetic relationships. 2011 , 7, 63-77		6

761	Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. 2011 , 29, 1125-32	910
760	The β -Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior. 2011 , 7, 1233-43	3
759	Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. 2011 , 29, 615-24	114
758	Pharmacology of Chiral Drugs. 2011 , 323-345	3
757	Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. 2011 , 2, 769-91	26
756	Quality assessment of bioanalytical quantification of monoclonal antibody drugs. 2011 , 2, 383-96	7
755	Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. 2011 , 50, 131-42	118
754	Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. 2011 , 50, 793-807	70
753	Pharmacokinetics in Drug Development. 2011 ,	20
752	Addressing new analytical challenges in protein formulation development. 2011 , 78, 196-207	24
751	Physiologically-based pharmacokinetics in drug development and regulatory science. 2011 , 51, 45-73	472
750	Regulatory considerations for development of bioanalytical assays for biotechnology products. 2011 , 3, 597-603	16
749	Mechanisms of monoclonal antibody-drug interactions. 2011 , 51, 359-72	66
748	Cooperation of dendritic cells with naive lymphocyte populations to induce the generation of antigen-specific antibodies in vitro. 2011 , 156, 173-81	4
747	Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. 2011 , 11, 532-8	60
746	Pharmacokinetics of Immunoglobulin G and Serum Albumin: Impact of the Neonatal Fc Receptor on Drug Design. 2011 , 85-120	
745	Monoclonal antibodies: interspecies scaling with minimal preclinical information. 2011 , 2, 359-68	9
744	Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 283-90 ⁶¹	39

743	Use of unbound volumes of drug distribution in pharmacokinetic calculations. 2011 , 42, 91-8		12
742	Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized <i>Pichia pastoris</i> with specific glycoforms: a comparative study with CHO produced materials. 2011 , 39, 205-10		62
741	Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. 2011 , 139, 133-41		81
740	Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. 2011 , 13, 99-110		198
739	Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1469-77	4	124
738	Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components. 2011 , 38, 581-93		3
737	Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. 2011 , 38, 769-86		19
736	Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. 2011 , 26, 19-26		570
735	Ectopic expression of human mTOR increases viability, robustness, cell size, proliferation, and antibody production of chinese hamster ovary cells. 2011 , 108, 853-66		72
734	Electrostatic interactions of monoclonal antibodies with subcutaneous tissue. 2011 , 2, 727-36		31
733	Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- α in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. 2011 , 70, 1542-9		94
732	Bioanalytical considerations in the comparability assessment of biotherapeutics. 2011 , 3, 613-22		9
731	Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?. <i>MABs</i> , 2011 , 3, 61-6	6.6	202
730	Intravitreal concentrations of a near-infrared fluorescence-labeled biotherapeutic determined in situ using confocal scanning laser ophthalmoscopy. 2011 , 52, 6949-58		2
729	Free versus total ligand-binding assays: points to consider in biotherapeutic drug development. 2011 , 3, 1163-5		13
728	Clinical Trial Simulations. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011 ,	0.5	12
727	Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. 2011 , 17, 6329-37		77
726	Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. <i>MABs</i> , 2012 , 4, 101-9	6.6	55

725	Clinical pharmacology considerations in biologics development. 2012 , 33, 1339-47		56
724	Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. 2012 , 72, 1632-41		28
723	Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics. 2012 , 4, 2513-23		18
722	A strategy for risk mitigation of antibodies with fast clearance. <i>MABs</i> , 2012 , 4, 753-60	6.6	150
721	Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. <i>MABs</i> , 2012 , 4, 267-73	6.6	33
720	Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 18-28	2.9	25
719	High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. 2012 , 3, 889-900		40
718	GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. 2012 , 34, 2268-78		55
717	ADME of biologics-what have we learned from small molecules?. 2012 , 14, 410-9		41
716	Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. 2012 , 14, 445-55		20
715	Mechanistic determinants of biotherapeutics absorption following SC administration. 2012 , 14, 559-70		193
714	Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. 2012 , 14, 554-8		88
713	Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice. 2012 , 29, 3180-7		1
712	Application of knockout mouse models to investigate the influence of FcR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. <i>International Journal of Pharmaceutics</i> , 2012 , 439, 8-16	6.5	22
711	Metabolism of biologics: biotherapeutic proteins. 2012 , 4, 189-95		16
710	High-throughput method development for sensitive, accurate, and reproducible quantification of therapeutic monoclonal antibodies in tissues using orthogonal array optimization and nano liquid chromatography/selected reaction monitoring mass spectrometry. 2012 , 84, 4373-82		59
709	Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. 2012 , 287, 11090-7		131
708	Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. 2012 , 9, 281-9		24

707	Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. <i>MAbs</i> , 2012 , 4, 466-74	6.6	22
706	Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. 2012 , 109, 16095-100		35
705	Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis. 2012 , 1251, 63-73		39
704	Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. 2012 , 101, 4367-82		27
703	The Diverse Roles of FcRn: Implications for Antibody Engineering. 2012 , 207-222		
702	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins. 2012 , 337-367		4
701	Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. 2012 , 51, 247-60		60
700	Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1 β monoclonal antibody. 2012 , 51, e1-18		124
699	Local versus systemic anti-tumour necrosis factor- α effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug. 2012 , 51, 443-55		14
698	Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 91, 635-46	6.1	349
697	In search of physiologically based distribution volume estimates for macromolecules. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 419-21	6.1	5
696	Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol). 2012 , 23, 1452-62		38
695	General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. 2012 , 84, 1267-73		159
694	Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells. 2012 , 29, 2923-31		14
693	Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. 2012 , 14, 850-9		79
692	Development of Antibody-Based Therapeutics. 2012 ,		5
691	Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. 2012 , 14, 714-27		32
690	A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. 2012 , 18, 1570-4		301

689	Disposition of Biological Therapeutics: Monoclonal Antibodies, Proteins, and Peptides. 2012 , 1	
688	Safety Updates on Tumor Necrosis Factor Blockers. 2012 , 18a, 98-109	
687	Image guided biodistribution and pharmacokinetic studies of theranostics. 2012 , 2, 1040-53	87
686	Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. 2012 , 3, 73-92	161
685	Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?. 2012 , 8, 141-60	92
684	Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability. 2012 , 101, 3763-78	9
683	Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. 2012 , 14, 612-8	48
682	Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. 2012 , 56, 4569-82	69
681	Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. 2012 , 14, 252-61	29
680	Simple scale-up of recombinant antibody production using an UCOE containing vector. 2012 , 29, 477-84	35
679	Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?. 2012 , 26 Suppl 5, 9-16	6
678	Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. 2012 , 402, 1229-39	49
677	Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. 2012 , 29, 490-9	68
676	Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. 2012 , 29, 866-82	36
675	Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. 2012 , 39, 67-86	230
674	Bioavailability of IgG administered by the subcutaneous route. 2013 , 33, 984-90	65
673	Novel Biopharmaceuticals. 2013 , 97-137	4
672	Development of a validated liquid chromatography tandem mass spectrometry assay for a PEGylated adnectin in cynomolgus monkey plasma using protein precipitation and trypsin digestion. 2013 , 934, 1-7	19

671	Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock. 2013 , 14, 17		23
670	Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development. 2013 , 15, 717-27		8
669	Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. 2013 , 15, 377-87		70
668	Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. 2013 , 15, 551-8		14
667	The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. 2013 , 15, 172-82		26
666	Population pharmacokinetics of sifalimumab, an investigational anti-interferon- γ monoclonal antibody, in systemic lupus erythematosus. 2013 , 52, 1017-27		20
665	Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. 2013 , 40, 597-607		94
664	Mapping biological behaviors by application of longer-lived positron emitting radionuclides. 2013 , 65, 1098-111		32
663	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MABs</i> , 2013 , 5, 826-37	6.6	83
662	Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. 2013 , 127, 2222-30		64
661	Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. 2013 , 52, 83-124		159
660	Analytical lessons learned from selected therapeutic protein drug comparability studies. 2013 , 41, 131-47		56
659	Mechanisms of subcutaneous absorption of rituximab in rats. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 248-55	4	35
658	Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?. 2013 , 56, 660-74		44
657	Application of knockout mouse models to investigate the influence of FcR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. <i>International Journal of Pharmaceutics</i> , 2013 , 444, 185-92	6.5	11
656	Pharmacokinetic studies of protein drugs: past, present and future. 2013 , 65, 1065-73		45
655	Prediction of drug disposition on the basis of its chemical structure. 2013 , 52, 415-31		21
654	Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. 2013 , 10, 907-26		68

653	Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 711-20	2.9	34
652	Future of coagulation factor replacement therapy. 2013 , 11 Suppl 1, 84-98		48
651	A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics. 2013 , 15, 1141-54		35
650	Are hepatic impairment studies necessary for therapeutic proteins?. 2013 , 35, 1444-51		9
649	Protein-polyanion interactions for the controlled release of monoclonal antibodies. 2013 , 14, 75-83		27
648	Pharmacokinetic and pharmacodynamic modeling of drug absorption and delivery. 2013 , 24-38		
647	Inhibition of calcitonin gene-related peptide (CGRP) has the potential to extend first-phase insulin secretion. 2013 , 121, 280-5		12
646	Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. <i>MABs</i> , 2013 , 5, 297-305	6.6	124
645	Monitoring antigen-specific biologics: current knowledge and future prospects. 2013 , 35, 588-94		11
644	Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20. 2013 , 51, 537-48		13
643	Engineering and characterization of the chimeric antibody that targets the C-terminal telopeptide of the α 1 chain of human collagen I: a next step in the quest to reduce localized fibrosis. 2013 , 54, 187-96		11
642	The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 314-25	2.9	71
641	Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects. 2013 , 2, 349-57		21
640	Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAB), in patients with advanced solid tumors. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 1103-11	2.9	26
639	Pharmacology of AMG 181, a human anti- α 4 β 7 antibody that specifically alters trafficking of gut-homing T cells. 2013 , 169, 51-68		33
638	Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies. 2013 , 102, 2898-908		13
637	Nonclinical Safety Assessment of Biologics, Including Vaccines. 2013 , 1-26		
636	A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. 2013 , 19, 3659-70		151

635	Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments. <i>MAbs</i> , 2013 , 5, 288-96	6.6	10
634	Implications of continued response after autologous stem cell transplantation for multiple myeloma. 2013 , 122, 1746-9		18
633	The development of antibody-based immunotherapy for methamphetamine abuse: immunization, and virus-mediated gene transfer approaches. 2013 , 13, 39-50		14
632	Neonatal Fc receptor and its role in the absorption, distribution, metabolism and excretion of immunoglobulin G-based biotherapeutics. 2013 , 14, 764-90		38
631	. 2014 ,		4
630	Anti-TNF therapeutics for the treatment of sarcoidosis. 2014 , 6, 1127-43		35
629	Subcutaneous absorption of biotherapeutics: knowns and unknowns. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1881-9	4	125
628	The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis. 2014 , 6, 1827-41		19
627	Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 1047-55	3.5	28
626	Quantitation of human peptides and proteins via MS: review of analytically validated assays. 2014 , 6, 1843-57		33
625	Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. 2014 , 41, 571-80		30
624	Pharmacokinetic modeling of the subcutaneous absorption of therapeutic proteins. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1890-905	4	44
623	Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum. <i>MAbs</i> , 2014 , 6, 1103-13	6.6	16
622	Canakinumab for gout: a specific, patient-profiled indication. 2014 , 10, 339-47		9
621	Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice. 2014 , 19, 16022		7
620	Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?. 2014 , 9, 323-30		8
619	Targeted treatments of bone metastases in patients with lung cancer. 2014 , 4, 146		10
618	The effect of the neonatal Fc receptor on human IgG biodistribution in mice. <i>MAbs</i> , 2014 , 6, 502-8	6.6	33

617	A phase 1 study investigating DX-2930 in healthy subjects. 2014 , 113, 460-6.e2		41
616	Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. 2014 , 6, 1436-54		39
615	Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. 2014 , 12, 1137-44		11
614	The effects of a humanized recombinant anti-cocaine monoclonal antibody on the disposition of cocaethylene in mice. 2014 , 23, 387-90		12
613	Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients. 2014 , 103, 328-36		17
612	Chapter 11:Human Microdosing/Phase 0 Studies to Accelerate Drug Development. 2014 , 241-266		
611	A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed?. <i>Journal of Clinical Pharmacology</i> , 2014 , 54, 483-94	2.9	34
610	Pharmacokinetics considerations for gout treatments. 2014 , 10, 949-57		10
609	The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 477-87	3.8	28
608	In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. 2014 , 111, 18601-6		138
607	Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. 2014 , 6, 48-57		87
606	Quantification of patient-specific assay interference in different formats of enzyme-linked immunoassays for therapeutic monoclonal antibodies. 2014 , 36, 765-70		8
605	A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design. <i>MABs</i> , 2014 , 6, 1094-102	6.6	26
604	Microscale receiver operating characteristic analysis of micrometastasis recognition using activatable fluorescent probes indicates leukocyte imaging as a critical factor to enhance accuracy. 2014 , 19, 066006		4
603	Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. <i>Frontiers in Pharmacology</i> , 2014 , 5, 174	5.6	103
602	Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1858-66	4	38
601	Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. 2014 , 56, 65-9		30
600	In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice. 2014 , 31, 216-27		30

599	Antibodies for treatment of Clostridium difficile infection. 2014 , 21, 913-23	24
598	Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. 2014 , 31, 3265-73	15
597	Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain. 2014 , 1, 659-69	11
596	The pharmacokinetics and safety profiles of belimumab after single subcutaneous and intravenous doses in healthy Japanese volunteers. 2014 , 39, 97-101	13
595	Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. 2014 , 3, e138	12
594	Antibody Affinity. 2014 , 115-140	3
593	Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. 2014 , 11, 1591-8	34
592	Effects of calibration approaches on the accuracy for LC-MS targeted quantification of therapeutic protein. 2014 , 86, 3575-84	44
591	The challenge of indication extrapolation for infliximab biosimilars. 2014 , 42, 177-83	120
590	βsynuclein immunotherapy blocks uptake and templated propagation of misfolded βsynuclein and neurodegeneration. 2014 , 7, 2054-65	237
589	Pharmacokinetics of Peptide-Fc fusion proteins. 2014 , 103, 53-64	53
588	Controlled release of therapeutic antibody formats. 2014 , 88, 291-309	33
587	Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period. 2014 , 32, 6213-9	11
586	FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. 2014 , 382, 249-72	47
585	Fc Receptors. 2014 ,	8
584	Biothérapies par voie sous-cutanée : modalités d'absorption et implications cliniques. 2014 , 16, 393-400	
583	Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. 2014 , 41, 375-87	61
582	Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. 2014 , 16, 129-39	33

581	Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies. 2014 , 16, 810-42		9
580	Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. 2014 , 16, 1009-17		14
579	Assessment of the metabolism of therapeutic proteins and antibodies. 2014 , 10, 1079-91		15
578	Generic automated method for liquid chromatography-multiple reaction monitoring mass spectrometry based monoclonal antibody quantitation for preclinical pharmacokinetic studies. 2014 , 86, 8776-84		48
577	A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis. 2014 , 45 Suppl 1, 161-5		3
576	Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent. <i>Clinical Drug Investigation</i> , 2014 , 34, 373-82	3.2	2
575	The history of monoclonal antibody development - Progress, remaining challenges and future innovations. 2014 , 3, 113-6		236
574	PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice. <i>International Journal of Pharmaceutics</i> , 2014 , 465, 228-38	6.5	19
573	Bioanalytical Methods and Immunogenicity Assays. 2014 , 207-242		
572	The Pharmacokinetics of Biologics: A Primer. 2015 , 33 Suppl 1, 61-69		40
571	A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. 2015 , 30, 216-24		204
570	[(64) Cu]-labelled trastuzumab: optimisation of labelling by DOTA and NODAGA conjugation and initial evaluation in mice. 2015 , 58, 227-33		12
569	Application of Mechanistic Pharmacokinetic/Pharmacodynamic Modeling toward the Development of Biologics. 2015 , 109-134		1
568	Antibody-drug conjugates as novel anti-cancer chemotherapeutics. 2015 , 35,		237
567	Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S51-9	2.9	39
566	Riloncept pharmacokinetics in children with systemic juvenile idiopathic arthritis. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 39-44	2.9	8
565	Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 957-64	3.8	12
564	The high-affinity receptor for IgG, FcRI, of humans and non-human primates. 2015 , 268, 175-91		11

563	Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S75-84	2.9	26
562	Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S85-92	2.9	3
561	A systematic study of glycopeptide esterification for the semi-quantitative determination of sialylation in antibodies. 2015 , 29, 1817-26		20
560	Studies of nontarget-mediated distribution of human full-length IgG1 antibody and its FAb fragment in cardiovascular and metabolic-related tissues. 2015 , 104, 1825-31		3
559	Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1337-49	3.8	17
558	Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. 2015 , 181, 179-87		13
557	Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. 2015 , 36, 115-25		16
556	Acute Treatment With XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice. 2015 , 116, 2109-19		5
555	Profile of secukinumab in the treatment of psoriasis: current perspectives. 2015 , 11, 1767-77		15
554	Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. 2015 , 3, 149-181		19
553	Fully human monoclonal antibody inhibitors of the neonatal Fc receptor reduce circulating IgG in non-human primates. 2015 , 6, 176		32
552	New developments in atherosclerosis: clinical potential of PCSK9 inhibition. 2015 , 11, 493-501		16
551	Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines. 2015 , 7, 6441-57		33
550	Biologic concentration testing in inflammatory bowel disease. 2015 , 21, 1435-42		49
549	Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization. 2015 , 2015, 874916		14
548	Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. 2015 , 58, 4665-77		23
547	ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice. 2015 , 14, 129-40		71
546	Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. 2015 , 290, 29732-41		43

545	Automated, Online Sample Preparation for LC-MS Analyses: Affinity Capture, Digestion, and Clean-Up. 2015 , 335-356	1
544	Hybrid imaging of fluorescently labeled cancer drugs and label-free four-wave mixing microscopy of cancer cells and tissues. 2015 , 20, 86006	3
543	Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. 2015 , 11, 93-108	13
542	Sclerostin and skeletal health. 2015 , 16, 149-56	23
541	Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. 2015 , 56, 956-61	85
540	Nebulization as a delivery method for mAbs in respiratory diseases. 2015 , 12, 1027-39	65
539	Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. 2016 , 36, 506-20	22
538	Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. 2015 , 42, 1-18	19
537	The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. 2015 , 91, 109-24	125
536	Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. 2015 , 17, 389-99	38
535	Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticals. 2015 , 32, 286-99	19
534	Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. 2015 , 32, 3470-9	71
533	Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects. 2015 , 16, 1101-7	34
532	Protein- and Peptide-drug conjugates: an emerging drug delivery technology. 2015 , 98, 1-55	49
531	Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. 2015 , 4, e989776	20
530	Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS. 2015 , 28, 513-20	42
529	A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components. 2015 , 214, 94-102	46
528	Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. 2015 , 54, 1107-23	72

527	Key protection factors against tetanus: Anti-tetanus toxin antibody affinity and its ability to prevent tetanus toxin - ganglioside interaction. 2015 , 103, 135-44		11
526	Ethnic sensitivity assessment - pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs. 2015 , 11, 179-91		16
525	Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S39-50	2.9	61
524	Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. 2015 , 32, 3269-81		37
523	Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. 2015 , 46, 175-85		91
522	Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. <i>MAbs</i> , 2015 , 7, 265-75	6.6	52
521	Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. 2015 , 41, 1094-103		65
520	Targeting FcRn for the modulation of antibody dynamics. 2015 , 67, 131-41		61
519	Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection. 2015 , 17, 828-36		27
518	Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 ,	0.5	6
517	Tailoring recombinant protein quality by rational media design. 2015 , 31, 615-29		57
516	An enzyme-linked immunosorbent assay with a new way to control the edge effect and its application for bevacizumab pharmacokinetic studies in beagle dogs by fitting with a new pharmacokinetic model. 2015 , 7, 8936-8941		1
515	New treatments of osteoporosis. 2015 , 1, 4-21		9
514	Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. 2015 , 13, 743-54		166
513	A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. <i>MAbs</i> , 2015 , 7, 912-28.6		35
512	Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naïve cynomolgus monkeys. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 762-70	4	12
511	Measurement of Free Versus Total Therapeutic Monoclonal Antibody in Pharmacokinetic Assessment is Modulated by Affinity, Incubation Time, and Bioanalytical Platform. 2015 , 17, 1446-54		14
510	Key interactions of surfactants in therapeutic protein formulations: A review. 2015 , 97, 60-7		124

509	Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis. <i>MABs</i> , 2015 , 7, 1195-204	6.6	11
508	LC-MS-based quantification of intact proteins: perspective for clinical and bioanalytical applications. 2015 , 7, 1943-58		45
507	A novel immunoassay to measure total serum lymphotoxin-H levels in the presence of an anti-LT β therapeutic antibody. 2015 , 424, 91-9		2
506	Adapting to Biology: Maintaining Container-Closure System Compatibility with the Therapeutic Biologic Revolution. 2015 , 69, 219-235		
505	Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. 2015 , 54, 35-80		31
504	A phase IIa randomised clinical study of GNBAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. 2015 , 21, 885-93		40
503	Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB β Drug Conjugates. 2015 , 32, 1884-93		34
502	Probing the extracellular diffusion of antibodies in brain using in vivo integrative optical imaging and ex vivo fluorescence imaging. 2015 , 197, 78-86		42
501	Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN- γ IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. 2015 , 32, 640-53		26
500	Network biology in development of monoclonal antibody therapeutics. 2015 , 260, 6-10		
499	New Therapeutic Strategies in Lung Cancers. 2015 ,		0
498	Pharmaceutical Dosage Forms - Parenteral Medications. 2016 ,		1
497	An update on antibody-based immunotherapies for Clostridium difficile infection. 2016 , 9, 209-24		16
496	Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. 2016 , 10, 4005-4016		20
495	Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. 2016 , 10, 3685-3698		30
494	Matrix metalloproteinase protein inhibitors: highlighting a new beginning for metalloproteinases in medicine. 2016 , Volume 3, 31-47		19
493	. 2016 ,		4
492	Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. 2016 , 22, 1999-2015		71

491	Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. 2016 , 43, 427-46		44
490	Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 1516-1527	2.9	29
489	Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. 2016 , 21-22, 75-83		89
488	Therapeutic Monoclonal Antibodies and Their Targets. 2016 , 113-153		
487	A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays. 2016 , 22, 2289-301		27
486	Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice. 2016 , 105, 1693-1704		18
485	Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 987-96	3.5	4
484	In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. 2016 , 4, 43-54		9
483	Allometric Scaling of Therapeutic Monoclonal Antibodies Using Antigen Concentration as a Correction Factor: Application to the Human Clearance Prediction. 2016 , 105, 1335-40		5
482	Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey. 2016 , 18, 948-59		7
481	Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GnbAC1 to treat multiple sclerosis: A Phase 1 study. <i>MABs</i> , 2016 , 8, 854-60	6.6	15
480	Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. 2016 , 21, 535-6		40
479	A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. 2016 , 127, 1633-41		163
478	Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies. 2016 , 38, 2083-2097.e7		10
477	Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. 2016 , 5, 516-531		139
476	Ustekinumab for the treatment of Crohn's disease. 2016 , 10, 989-94		5
475	Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. 2016 , 5, 102-8		19
474	Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects. 2016 , 5, 208-15		17

473	Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. 2016 , 37, 51-65	39
472	Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. 2016 , 16, 1131-9	12
471	A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease. 2016 , 111, 1438-1445	41
470	Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. 2016 , 13, 3241-6	13
469	A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins. 2016 , 18, 156-70	48
468	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. 2016 , 3, 16068	41
467	Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development. 2016 , 9, 747-9	14
466	Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. 2016 , 72, 1343-1352	4
465	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients. 2016 , 5, 408-25	1
464	Pharmacokinetics interactions of monoclonal antibodies. 2016 , 111, 592-599	58
463	In vivo imaging of tumour xenografts with an antibody targeting the potassium channel K10.1. 2016 , 45, 721-733	15
462	Steady-state volume of distribution of two-compartment models with simultaneous linear and saturated elimination. 2016 , 43, 447-59	5
461	ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. 2016 , 43, 2169-2179	17
460	Pharmacokinetics of AntibodyDrug Conjugates. 2016 , 245-266	
459	Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications. 2016 , 8, 1427-1436	8
458	Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. 2016 , 3, e000146	45
457	Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. 2016 , 38, 567-72	12
456	Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy. 2016 , 40, 1326-33	7

455	Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients. 2016 , 37, 107-19		5
454	Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. 2016 , 25, 1448-1455		21
453	Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. 2016 , 16, 1285-1300		54
452	Automated DBS microsampling, microscale automation and microflow LC-MS for therapeutic protein PK. 2016 , 8, 649-59		9
451	Monoclonal Antibody Pharmacokinetics in Type 2 Diabetes Mellitus and Diabetic Nephropathy. 2016 , 2, 45-56		24
450	Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. 2016 , 38, 1417-1434.e2		2
449	Population physiologically-based pharmacokinetic model incorporating lymphatic uptake for a subcutaneously administered pegylated peptide. 2016 , 4, 3		10
448	Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 157-69	2.9	75
447	Myostatin inhibitors in sports drug testing: Detection of myostatin-neutralizing antibodies in plasma/serum by affinity purification and Western blotting. 2016 , 10, 195-205		8
446	Isomerization and Oxidation in the Complementarity-Determining Regions of a Monoclonal Antibody: A Study of the Modification-Structure-Function Correlations by Hydrogen-Deuterium Exchange Mass Spectrometry. 2016 , 88, 2041-50		54
445	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 389-96	5.4	29
444	Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. 2016 , 113, E459-68		240
443	Antibody-mediated delivery of therapeutics for cancer therapy. 2016 , 13, 401-19		31
442	Antibody-targeted biodegradable nanoparticles for cancer therapy. 2016 , 11, 63-79		64
441	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. 2016 , 22, 858-67		13
440	Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. <i>MAbs</i> , 2016 , 8, 229-45	6.6	77
439	CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. <i>MAbs</i> , 2016 , 8, 867-78	6.6	31
438	Clinical Decision Support Tools: The Evolution of a Revolution. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 405-18	6.1	51

437	Subcutaneous administration of monoclonal antibodies: a small space to inject, a big challenge to conquer. 2016 , 7, 5-6		
436	Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1. 2016 , 30, 1927-40		51
435	Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. 2016 , 13, 1229-41		22
434	Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies. 2016 , 431, 45-51		17
433	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. 2016 , 34, 1097-103		141
432	Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics. 2016 , 55, 789-805		37
431	Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification. 2016 , 916, 112-9		25
430	Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. 2016 , 54, 1085-93		33
429	A novel pharmacokinetic model based on the complex elimination of monoclonal antibodies for bevacizumab pharmacokinetic study in rabbits. 2016 , 31, 39-44		3
428	A subcutaneous cellular implant for passive immunization against amyloid- β reduces brain amyloid and tau pathologies. 2016 , 139, 1587-604		23
427	Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. <i>MABs</i> , 2016 , 8, 761-74	6.6	16
426	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. 2016 , 27, 214-24		67
425	Secukinumab for treating plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 119-28	5.4	16
424	Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry. 2017 , 36, 734-754		42
423	Enhancement of antibody functions through Fc multiplications. <i>MABs</i> , 2017 , 9, 393-403	6.6	10
422	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. 2017 , 45, 617-630		50
421	Complementary and Alternative Medicine Use in Rheumatoid Arthritis: Considerations for the Pharmacological Management of Elderly Patients. 2017 , 34, 255-264		16
420	Antibody Neutralization of CXCL10 Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES. 2017 , 292, 4185-4197		11

419	Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 876-885	2.9	29
418	Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. 2017 , 77, 363-377		25
417	Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1782-1790	3.8	28
416	Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation. 2017 , 19, 610-616		21
415	Considerations for dosing immunoglobulin in obese patients. 2017 , 188, 353-362		22
414	Golimumab for moderate to severe ulcerative colitis. 2017 , 11, 401-406		6
413	Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 1017-1030	2.9	20
412	Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis. 2017 , 106, 2853-2859		21
411	Tumor necrosis factor inhibitors in psoriatic arthritis. 2017 , 10, 899-910		22
410	Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study. 2017 , 30, 1110-1118		6
409	Pharmacokinetics of Bispecific Antibody. 2017 , 3, 126-137		12
408	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. 2017 , 169, 610-620.e14		139
407	Photo-Modulated Therapeutic Protein Release from a Hydrogel Depot Using Visible Light. 2017 , 129, 986-991		20
406	Photo-Modulated Therapeutic Protein Release from a Hydrogel Depot Using Visible Light. 2017 , 56, 966-971		48
405	Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens. <i>MAbs</i> , 2017 , 9, 297-306	6.6	8
404	Ultra-performance liquid chromatography/multiple reaction monitoring mass spectrometry quantification of trastuzumab in human serum by selective monitoring of a specific peptide marker from the antibody complementarity-determining regions. 2017 , 31, 1184-1192		13
403	New treatments for headache. 2017 , 38, 145-156		5
402	The Application of Immunoaffinity-Based Mass Spectrometry to Characterize Protein Biomarkers and Biotherapeutics. 2017 , 67-89		

401	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. 2017 , 39, 322-326		18
400	The Use of Microdosing in the Development of Small Organic and Protein Therapeutics. 2017 , 58, 1188-1195		14
399	Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. 2017 , 34, 1784-1795		58
398	Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation. 2017 , 56, 1081-1089		5
397	Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 947-955	2.9	3
396	Canakinumab for the treatment of familial Mediterranean fever. 2017 , 13, 393-404		28
395	Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. 2017 , 34, 1556-1563		10
394	An apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 661-671	3.5	7
393	Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. 2017 , 56, 1513-1523		21
392	Cancer immunotherapy targeting the CD47/SIRPα axis. 2017 , 76, 100-109		197
391	ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. 2017 , 14, 1646-1655		25
390	Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines. 2017 , 10, 273-283		14
389	Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 305-312	6.1	79
388	Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches. 2017 , 595, 7311-7330		27
387	Target-Specific Delivery of an Antibody That Blocks the Formation of Collagen Deposits in Skin and Lung. 2017 , 36, 199-207		2
386	Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma. 2017 , 409, 6583-6593		15
385	Blocking CGRP in migraine patients - a review of pros and cons. 2017 , 18, 96		147
384	Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates. 2017 , 44, 537-548		8

383	Donor-Derived Metastatic Melanoma and Checkpoint Inhibition. 2017 , 49, 1551-1554		16
382	Pharmacokinetics of Therapeutic Proteins. 2017 , 311-340		1
381	A novel model for the pharmacokinetic studies of bevacizumab and etanercept in healthy volunteers and patients. 2017 , 145, 169-177		2
380	Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. 2017 , 46, 603-626		40
379	Investigation of the Influence of Protein-Losing Enteropathy on Monoclonal Antibody Pharmacokinetics in Mice. 2017 , 19, 1791-1803		3
378	Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. 2017 , 34, 2579-2595		22
377	Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab. 2017 , 17, 607-613		6
376	Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals. <i>MABs</i> , 2017 , 9, 1379-1388	6.6	4
375	TNF- α and IL-6 inhibitors: Conjugates of N-substituted indole and aminophenylmorpholin-3-one as anti-inflammatory agents. 2017 , 140, 92-103		28
374	Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. 2017 , 13, 1039-1046		35
373	Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. 2017 , 23, 1454-1460		16
372	Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points. 2017 , 19, 1487-1498		37
371	Nonantimicrobial drug targets for <i>Clostridium difficile</i> infections. 2017 , 12, 975-985		3
370	Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site. 2017 , 44, 463-475		6
369	Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis. 2017 , 10, 1037-1047		3
368	Bezlotoxumab for the prevention of <i>Clostridium difficile</i> recurrence. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1439-1445	5-4	5
367	Anti-Psl Targeting of <i>Pseudomonas aeruginosa</i> Biofilms for Neutrophil-Mediated Disruption. 2017 , 7, 16065		25
366	Metal-Free Cycloaddition Chemistry Driven Pretargeted Radioimmunotherapy Using β Particle Radiation. 2017 , 28, 3007-3015		19

365	A role for macromolecular crowding in off-target binding of therapeutic antibodies. 2017 , 30, 489-494		4
364	Influence of Molecular size on the clearance of antibody fragments. 2017 , 34, 2131-2141		15
363	Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. 2017 , 65, 1988-1995		112
362	Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. 2017 , 19, 53		25
361	Novel Monoclonal Antibody Is an Allosteric Insulin Receptor Antagonist That Induces Insulin Resistance. 2017 , 66, 206-217		8
360	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. 2017 , 56, 635-647		16
359	Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. <i>MABs</i> , 2017 , 9, 15-28	6.6	7
358	Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. 2017 , 52, 567-569		4
357	ImmunoPET imaging of tissue factor expression in pancreatic cancer with Zr-Df-ALT-836. 2017 , 264, 160-168		10
356	Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	110
355	Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components. 2017 , 21, 131-41		31
354	CD4+ levels control the odds of induction of humoral immune responses to tracer doses of therapeutic antibodies. 2017 , 12, e0187912		2
353	Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction. 2017 , 13, 41		5
352	Denosumab: Renal Safety Evaluation. 2017 , 1, 127-131		
351	Profile of romosozumab and its potential in the management of osteoporosis. 2017 , 11, 1221-1231		35
350	Safety, tolerability, and preliminary activity of IMG529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. 2018 , 36, 869-876		22
349	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. 2018 , 57, 1075-1106		10
348	Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans. 2018 , 35, 47		6

347	A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. 2018 , 38, 1960-1971		32
346	Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. 2018 , 61, 672-692		11
345	Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. 2018 , 57, 1593-1601		6
344	Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. <i>MABs</i> , 2018 , 10, 751-764	6.6	32
343	TNF- α level affects etanercept clearance: TNF- α concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis. 2018 , 45, 643-651		4
342	Putting Out the Fire in Acute Kawasaki Disease. 2018 , 195, 11-13.e1		
341	Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins. 2018 , 107, 1247-1260		61
340	Competitive Affinity Release for Long-Term Delivery of Antibodies from Hydrogels. 2018 , 57, 3406-3410		23
339	Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection. 2018 , 61, 611-635		16
338	Population Pharmacokinetics of the TNF- α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 803-813	2.9	11
337	Reprogramming immune proteins as therapeutics using molecular engineering. 2018 , 19, 27-34		6
336	Tumor-Targeted Antibodies. 2018 , 311-319		
335	Immune Therapies in Phase 1 Trials. 2018 , 547-563		
334	A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. 2018 , 33, 150-158		5
333	Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMS. 2018 , 12, e1700120		9
332	Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy. 2018 , 233, 6441-6457		52
331	Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. 2018 , 57, 929-942		52
330	Adalimumab concentration-based tapering strategy: as good as the recommended dosage. 2018 , 77, 473-475		8

329	LCMS Challenges in Characterizing and Quantifying Monoclonal Antibodies (mAb) and Antibody-Drug Conjugates (ADC) in Biological Samples. 2018 , 4, 45-63		13
328	Evaluation of the Effects of Animal Growth and Previous Exposure on the Pharmacokinetics of Rituximab in Rats. 2018 , 107, 1987-1994		0
327	Competitive Affinity Release for Long-Term Delivery of Antibodies from Hydrogels. 2018 , 130, 3464-3468		1
326	Pros and cons of different therapeutic antibody formats for recombinant antivenom development. 2018 , 146, 151-175		74
325	Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. 2018 , 9, 15-32		139
324	Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 815-825	6.1	53
323	Frontiers of monoclonal antibodies: Applications in medical practices. 2017 , 26, 135-142		3
322	Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. <i>MABs</i> , 2018 , 10, 81-94	6.6	36
321	Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections. 2018 , 29, 452-466		8
320	A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. 2018 , 45, 235-257		39
319	Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation. 2018 , 272, 62-71		22
318	Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans. 2018 , 7, 652-660		9
317	Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases. 2018 , 74, 161-169		25
316	The Clinical Pharmacology of Elotuzumab. 2018 , 57, 297-313		4
315	Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals. 2018 , 43, 103-113		3
314	Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology Products. 2018 , 14, e34-e41		4
313	P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. 2018 , 6, 3063-3074		9
312	Brain Theranostics and Radiotheranostics: Exosomes and Graphenes In Vivo as Novel Brain Theranostics. 2018 , 52, 407-419		4

311	Basic Considerations for the Use of Monoclonal Antibodies in Migraine. 2018 , 58, 1689-1696			16
310	Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools. 2018 , 15, 5697-5710			33
309	Improved Biodistribution and Extended Serum Half-Life of a Bacteriophage Endolysin by Albumin Binding Domain Fusion. 2018 , 9, 2927			26
308	[The Brazilian market for monoclonal antibodies used in cancer treatment]. 2018 , 34, e00010918			3
307	Absorption, Distribution, Metabolism, and Excretion of Biopharmaceutical Drug Products. 2018 , 241-270			
306	Accelerated Blood Clearance of Antibodies by Nanosized Click Antidotes. 2018 , 12, 12523-12532			4
305	ADME Processes in Pharmaceutical Sciences. 2018 ,			6
304	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. 2018 , 29, 3937-3966			15
303	Introduction to Biologic and Biosimilar Product Development and Analysis. <i>AAPS Introductions in the Pharmaceutical Sciences</i> , 2018 ,	0.2	0	
302	Cell Encapsulation. 2018 , 1-51			
301	Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective. 2018 , 20, 109			5
300	FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues. 2018 , 8,			19
299	Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?. 2018 , 20, 99			15
298	Antigens and Antibodies in Disease With Specifics About CGRP Immunology. 2018 , 58 Suppl 3, 230-237			4
297	Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance. <i>Drug Metabolism and Disposition</i> , 2018 , 46, 1900-1907	4	4	
296	Development and validation of generic heterogeneous fluoroimmunoassay for bioanalysis of bevacizumab and cetuximab monoclonal antibodies used for cancer immunotherapy. 2018 , 188, 562-569			1
295	Physiological responses of Chinese hamster ovary cells to a productivity-enhancing yeast extract. 2018 , 126, 636-643			1
294	Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. 2018 , 14, 585-599			32

293	Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. 2018 , 24, 2165-2172		17
292	Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2059-2074	3.8	5
291	Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. 2018 , 24, 2527-2542		20
290	Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling. <i>MAbs</i> , 2018 , 10, 1144-1156	6.6	18
289	High Sensitivity and Precision High-Temperature Reversed-Phase LC Analysis of Bevacizumab for Intact Bioanalysis of Therapeutic Monoclonal Antibodies. <i>Chromatography</i> , 2018 , 39, 21-26	1.2	10
288	Innate Immunity to Nanomaterials. 2018 , 389-407		2
287	Polysorbate Degradation and Quality. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2018 , 25-62	0.5	2
286	How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. 2018 , 12, 797-810		23
285	Large molecules with large pharmacokinetic variability: progress in pursuit of key considerations for intersubject variability. 2018 , 3, 57-60		1
284	The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. 2018 , 286, 154-166		13
283	Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model. 2018 , 367, 1-8		12
282	Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections. 2018 , 7,		25
281	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. 2018 , 50, 461-484		18
280	Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. 2018 , 285, 23-34		37
279	Label-Free Quantification of Anti-TNF- α in Patients Treated with Adalimumab Using an Optical Biosensor. 2018 , 18,		6
278	Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. <i>MAbs</i> , 2018 , 10, 803-813	6.6	17
277	Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 Tg-AD mice. 2018 , 10, 13		53
276	Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. 2018 , 45, 505-522		3

275	Targeting junctional adhesion molecule-C ameliorates sepsis-induced acute lung injury by decreasing CXCR4 aged neutrophils. 2018 , 104, 1159-1171		14
274	A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. 2018 , 16, 2184-2195		41
273	Structures of Hepatitis B Virus Core- and e-Antigen Immune Complexes Suggest Multi-point Inhibition. 2018 , 26, 1314-1326.e4		8
272	A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K, K, endosome trafficking, and animal species. <i>MAbs</i> , 2018 , 10, 1322-1331	6.6	11
271	A new era in headache treatment. 2018 , 39, 47-58		9
270	Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming. 2018 , 20, 76		11
269	Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. 2018 , 11, 540-552		80
268	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. 2019 , 58, 169-187		20
267	Defining Failure of Medical Therapy for Inflammatory Bowel Disease. 2019 , 25, 74-77		5
266	Two validated liquid chromatography-mass spectrometry methods with different pretreatments for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum compared with an electrochemiluminescence method. 2019 , 175, 112792		7
265	Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. 2019 , 33, 453-468		7
264	Immunomodulatory Methods. 2019 , 297-334		2
263	Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody. 2019 , 8, 676-684		6
262	Enterovirus type 71-immunized chicken egg yolk immunoglobulin has cross antiviral activity against coxsackievirus A16. 2019 , 18, 332-341		4
261	Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 1146-1155	4	11
260	Effect of Size on Solid Tumor Disposition of Protein Therapeutics. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 1136-1145	4	10
259	Subcutaneous delivery of biotherapeutics: challenges at the injection site. 2019 , 16, 143-151		21
258	Mechanism and Inhibition of Matrix Metalloproteinases. 2019 , 26, 2609-2633		19

257	Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. 2019 , 125, 16-25	7
256	Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. 2019 , 8,	13
255	Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effects of FcRn Inhibitors in Mice, Rats, and Monkeys. 2019 , 108, 701-713	11
254	Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. 2019 , 17, 127-145	23
253	Toxin Neutralization Using Alternative Binding Proteins. 2019 , 11,	17
252	Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates. 2019 , 14, e0217061	5
251	A Bioluminescence Resonance Energy Transfer-Based Approach for Determining Antibody-Receptor Occupancy In Vivo. 2019 , 15, 439-451	9
250	An evaluation of cetuximab dosing strategies using pharmacokinetics and cost analysis. 2019 , 71, 1222-1230	1
249	Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers. 2019 , 63,	24
248	Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. 2019 , 19, 519	19
247	Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. 2019 , 153, 3-13	19
246	An on-chip model of protein paracellular and transcellular permeability in the microcirculation. 2019 , 212, 115-125	39
245	Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics. 2019 , 370, 703-714	5
244	Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro. 2019 , 8,	7
243	Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 1100-1110	4 38
242	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. 2019 , 36, 93	2
241	Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1790-1797	3.8 6
240	Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. 2019 , 13, 1248-1256	26

239	Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis. 2019 , 58, 1059-1068		6
238	Modifications of recombinant monoclonal antibodies in vivo. 2019 , 59, 1-5		4
237	Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1495-1506	3.8	5
236	The monoclonal antibody GNBAC1: targeting human endogenous retroviruses in multiple sclerosis. 2019 , 12, 1756286419833574		16
235	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. 2019 , 37, 946-953		196
234	A new technology for increasing therapeutic protein levels in the brain over extended periods. 2019 , 14, e0214404		4
233	Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins. 2019 , 105-137		3
232	A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. 2019 , 39, 1284-1297		36
231	Modeling Approaches to Characterize Target-Mediated Pharmacokinetics and Pharmacodynamics for Therapeutic Proteins. 2019 , 149-172		
230	Cell Encapsulation. 2019 , 377-427		1
229	Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects Some Considerations. 2019 , 285-314		1
228	Mechanism and Physiologically Based PK/PD Model in Assisting Translation from Preclinical to Clinical: Understanding PK/PD of Therapeutic Proteins at Site-of-Action. 2019 , 43-64		
227	Translational Considerations in Developing Bispecific Antibodies: What Can We Learn from Quantitative Pharmacology?. 2019 , 187-208		
226	Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. 2019 , 7, 750-758		6
225	Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans. 2019 , 10, 674		1
224	New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies. <i>Frontiers in Pharmacology</i> , 2019 , 10, 363	5.6	35
223	A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs. <i>Pharmaceutics</i> , 2019 , 11,	6.4	7
222	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. 2019 , 58, 835-857		111

221	Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. 2019 , 26, 396-426		32
220	. 2019 ,		
219	20. Immunprophylaxe gegen die Antibiotika-assoziierte Diarrh� 2019 , 277-302		
218	Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. 2019 , 8,		22
217	Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 114-125	3.8	11
216	Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA�200 biosensor. 2019 , 192, 331-338		7
215	Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque Psoriasis. 2019 , 53, 276-284		7
214	Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. 2019 , 79, 841-852		15
213	Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 557-567	6.1	9
212	Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering. 2019 , 34, 25-41		14
211	Canakinumab for the treatment of hyperimmunoglobulin D syndrome. 2019 , 15, 215-220		2
210	Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 863-871	2.9	0
209	mRNA as novel technology for passive immunotherapy. 2019 , 76, 301-328		51
208	CGRP, Amylin, Immunology, and Headache Medicine. 2019 , 59, 131-150		17
207	Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models. 2019 , 108, 674-691		3
206	Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. 2019 , 33, 33-43		12
205	Non-invasive delivery strategies for biologics. 2019 , 18, 19-40		223
204	Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. 2019 , 34, 3-13		26

203	Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers. 2019 , 8, 702-712		20
202	Development of a flowchart for risk assessment and allocation of preparation of monoclonal antibodies. 2019 , 25, 187-191		3
201	Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I. 2019 , 58, 101-113		14
200	A Minimal Physiologically-Based Pharmacokinetic Model Demonstrates Role of the Neonatal Fc Receptor (FcRn) Competition in Drug-Disease Interactions With Antibody Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 423-434	6.1	3
199	Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 229-239	2.9	11
198	Accurate determination of drug-to-antibody ratio of interchain cysteine-linked antibody-drug conjugates by LC-HRMS. 2020 , 412, 833-840		4
197	Targeted Host Cell Protein Quantification by LC-MRM Enables Biologics Processing and Product Characterization. 2020 , 92, 1007-1015		13
196	Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. 2020 , 9, 882-893		2
195	The impact of body composition parameters on severe toxicity of nivolumab. 2020 , 124, 170-177		15
194	Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review. 2020 , 42, 45-56		7
193	Contribution of Intrinsic Fluorescence to the Design of a New 3D-Printed Implant for Releasing SDABS. <i>Pharmaceutics</i> , 2020 , 12,	6.4	1
192	The role of quantitative modeling and simulation in translational science. 2020 , 633-655		
191	Antibody based therapy in relapsed acute lymphoblastic leukemia. 2020 , 33, 101225		4
190	Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line. <i>MAbs</i> , 2020 , 12, 1844928	6.6	2
189	Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. 2020 , 42, 1494-1507.e1		4
188	Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity. <i>MAbs</i> , 2020 , 12, 1802135	6.6	6
187	Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance. 2020 , 34, 2152-2155		0
186	Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor-Mediated Recycling of HL2351, a Novel Hybrid Fc-Fused Interleukin-1 Receptor Antagonist, to Optimize Dosage Regimen. 2020 , 9, 584-595		1

185	Phase I Oncology Drug Development. 2020 ,		
184	Liquid chromatography-mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum. 2021 , 11, 472-479		1
183	Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review. 2021 , 11, 1818-1828		3
182	Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies. 2020 , 19, 1052-1058		2
181	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1753-1768	3.8	2
180	Target-mediated exposure enhancement: a previously unexplored limit of TMDD. 2020 , 47, 411-420		1
179	Vascular Drug Delivery Using Carrier Red Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. <i>Pharmaceutics</i> , 2020 , 12,	6.4	29
178	DLX1008 (brolocizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. 2020 , 15, e0233116		3
177	Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. 2020 , 109, 3172-3180		2
176	PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. 2020 , 14, 797-806		2
175	Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies. <i>MAbs</i> , 2020 , 12, 1770028	6.6	6
174	Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. 2020 , 11, 1088		22
173	Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease. 2020 , 11, 1148		1
172	Immunogenicity of TNF-Inhibitors. 2020 , 11, 312		39
171	Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids. 2020 , 72, 414-438		13
170	Exploiting antibody biology for the treatment of cancer. 2020 , 12, 255-267		3
169	Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. 2020 , 59, 857-874		16
168	Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?. 2020 , 128, 103-106		5

167	Dose Correction for a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model with a Multiple Intravenous Dosing Regimens. 2020 , 22, 30		2
166	A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men. 2020 , 9, 833-840		7
165	Biologicals in atopic disease in pregnancy: An EAACI position paper. 2021 , 76, 71-89		17
164	Anticalin proteins: from bench to bedside. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 509-518	5.4	5
163	Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs. 2021 , 330, 1191-1207		5
162	Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 688-699		2.9
161	Antibodies and antibody constructs as radiopharmaceuticals. 2021 ,		
160	rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapy. 2021 , 13, 79-88		
159	Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding. 2021 , 10, 1958590		1
158	Therapeutic antibody development Remington chapter. 2021 , 437-462		
157	Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment. 2021 , 41, 1549-1561		3
156	The ADME Encyclopedia. 2021 , 1-9		
155	Migraine. 2021 ,		
154	Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins. 2021 , 35, 125-146		8
153	Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention. 2021 , 37, 725-735		
152	Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
151	Immunoglobulin G Is a Novel Substrate for the Endocytic Protein Megalin. 2021 , 23, 40		1
150	Impact of body mass index on survival and serious adverse events in advanced non-small cell lung cancer treated with bevacizumab: a meta-analysis of randomized clinical trials. 2021 , 37, 811-817		3

149	Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. 2021 , 10,	6
148	The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases. 2021 , 26,	1
147	The effects of polyphenols-rich tropical fruit juice on cognitive function and metabolomics profile - a randomized controlled trial in middle-aged women. 2021 , 1-17	1
146	Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA). 2021 , 19, 59	0
145	GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. 2021 , 2, 100263	8
144	Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. 2021 , 14, 2012-2022	4
143	Antibody-Drug Conjugates-A Tutorial Review. 2021 , 26,	20
142	A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management. 2021 , 61, 838-853	1
141	Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties. <i>Pharmaceutics</i> , 2021 , 13,	6.4 1
140	Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. 2021 , 107925	1
139	Monoclonal Antibody Therapies for High Risk Neuroblastoma. 2021 , 15, 205-219	1
138	FcRn as a Transporter for Nasal Delivery of Biologics: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 1
137	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. 2021 , 11, 15057	2
136	A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants. 2021 , 9, e00813	
135	Impact of injection sites on clinical pharmacokinetics of subcutaneously administered peptides and proteins. 2021 , 336, 310-321	6
134	Engineering of single-domain antibodies for next-generation snakebite antivenoms. 2021 , 185, 240-250	2
133	Pharmacokinetics and Determination of Tumor Interstitial Distribution of a Therapeutic Monoclonal Antibody Using Large-Pore Microdialysis. 2021 , 110, 3061-3068	0
132	Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. 2021 , 1, 189-210	1

131	Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study. 2021 , 8, 1711-1724		
130	Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. 2021 ,		3
129	Secondary failure: immune responses to approved protein therapeutics. 2021 , 27, 1074-1083		0
128	Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity. 2021 , 20, 37		2
127	Safety, Pharmacokinetics, and Neutralizing Activity of SYN023, a Mixture of Two Novel Antirabies Monoclonal Antibodies Intended for Use in Post-rabies Exposure Prophylaxis. 2021 , 10, 807-817		4
126	Logistic Considerations in Study Design for Biologic Drug-Drug Interaction Assessments. 1		1
125	Biodistribution of Therapeutic Biologics: Methods and Applications in Informing Target Biology, Pharmacokinetics, and Dosing Strategies. 1-14		1
124	Pharmacokinetics and Half-Life of Protein Therapeutics. 23-38		6
123	Application of Modeling and Simulation in the Development of Protein Drugs. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2011 , 361-396	0.5	2
122	Microdosing: Pharmacokinetic and Metabolism Data Early in the Drug Development Process. 2011 , 115-130		1
121	Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics. 2013 , 101-132		8
120	Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 , 117-131	0.5	1
119	Discovery and Development of an Anti-methamphetamine Monoclonal Antibody for Use in Treating Methamphetamine Abuse. 2016 , 119-142		1
118	Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins. 2019 , 1148, 115-129		3
117	Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease. 2020 , 150, 105369		3
116	The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. 2020 , 212, 107574		5
115	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. 2021 , 6, 38-47		5
114	Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. 2018 , 3,		33

113	Orally administered P22 phage tailspike protein reduces salmonella colonization in chickens: prospects of a novel therapy against bacterial infections. 2010 , 5, e13904	75
112	HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. 2011 , 6, e18198	40
111	Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin. 2011 , 6, e24574	23
110	IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation. 2016 , 11, e0165248	4
109	Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. 2017 , 12, e0169845	32
108	Optical imaging probes in oncology. 2016 , 7, 48753-48787	37
107	Preclinical Study of the Pharmacokinetics of p75ECD-Fc, a Novel Human Recombinant Protein for Treatment of Alzheimer's Disease, in Sprague Dawley Rats. 2020 , 21, 235-244	4
106	The Influence of Different Disease States on Rituximab Pharmacokinetics. 2020 , 21, 938-946	4
105	ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies. 2020 , 17, 23-51	12
104	Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy. 2020 , 12,	14
103	Monoclonal antibodies as diagnostics; an appraisal. 2010 , 72, 12-7	40
102	Antibody fragments: Prolonging circulation half-life special issue-antibody research. 2013 , 04, 689-698	27
101	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. 2014 , 11, 20-33	91
100	Osteoporosis Management with Focus on Spine. 2021 , 61-92	
99	Subcutaneous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. 2021 , 2021,	78
98	Therapeutic antibodies - natural and pathological barriers and strategies to overcome them. 2021 , 108022	1
97	MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. 2021 , 13, eabj4011	19
96	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021 , 12, 6097	17.4 15

95	The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View. <i>Pediatrics and Farmakologija</i> , 2021 , 18, 304-313	0.5
94	Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics. 2012 , 303-330	
93	Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics. 2012 , 285-302	0
92	Biopharmaceutics of NCEs and NBEs. 2012 , 30-56	
91	Biomedicines as Adverse Event Inducers. 2014 , 593-623	
90	Denosumab. 2014 , 183-192	
89	Bone Metastases. 2015 , 225-244	
88	ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules. 1-11	
87	Review: The Critical Role of Clinical Pharmacology in the Development of Biologics. 1-16	
86	Role of Lymphatic System in Subcutaneous Absorption of Therapeutic Proteins. 1-10	
85	Prediction of Human Pharmacokinetics for Protein-Based Biologic Therapeutics. 1-16	
84	Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK, and PK/PD of Therapeutic Biologics. 1-22	1
83	Fixed Dosing versus Body-Size-Based Dosing for Therapeutic Biologics: A Clinical Pharmacology Strategy. 1-17	
82	Therapeutic Antibodies. <i>AAPS Introductions in the Pharmaceutical Sciences</i> , 2018 , 55-86	0.2
81	Special Populations. 2019 , 219-247	
80	A clinical trial protocol to evaluate the safety and pharmacokinetics of subcutaneously administered immunoglobulin in patients with primary immunodeficiency. <i>LymphoSign Journal</i> , 2019 , 6, 75-86	0.5
79	Development of Immunotherapeutic Strategies for Early Phase Clinical Trials. 2020 , 249-282	
78	Chapter 34: A Case Study of Bridging from a Lyophilizate Formulation to an Autoinjector for Patient Self-Administration. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2020 , 813-829	0.5

77	Prediction of subcutaneous drug absorption - do we have reliable data to design a simulated interstitial fluid?. <i>International Journal of Pharmaceutics</i> , 2021 , 610, 121257	6.5	3
76	Optical and Optoacoustic Imaging Probes. <i>Recent Results in Cancer Research</i> , 2020 , 216, 337-355	1.5	
75	Pharmacokinetics of Biologics. 2020 , 125-145		1
74	Nonclinical drug development. 2022 , 573-588		
73	Biotherapeutics ADME and PK/PD Principles. 2022 , 77-100		
72	Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. <i>MAbs</i> , 2021 , 13, 1994690	6.6	0
71	Transplacental Antibody Transfer of Respiratory Syncytial Virus Specific IgG in Non-Human Primate Mother-Infant Pairs. <i>Pathogens</i> , 2021 , 10,	4.5	0
70	Fluorescence Bioanalysis of Bevacizumab Using Pre-Column and Post-Column Derivatization □ Liquid Chromatography After Immunoaffinity Magnetic Purification. <i>Chromatography</i> , 2020 , 41, 115-122 ^{1,2}		0
69	Secukinumab for the Treatment of Inflammatory Skin and Joint Disease. 2021 , 243-251		
68	Antibody Therapeutics in Oncology. <i>Immunotherapy (Los Angeles, Calif)</i> , 2016 , 2,		9
67	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 478-489	0.7	1
66	A New Model to Describe the Single-dose Pharmacokinetics of Bevacizumab and Predict Its Multiple-Dose Pharmacokinetics in Beagle Dogs. <i>Iranian Journal of Pharmaceutical Research</i> , 2019 , 18, 1147-1155	1.1	
65	Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries. <i>MAbs</i> , 2021 , 13, 1980942	6.6	5
64	A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar. <i>Advances in Therapy</i> , 2021 , 1	4.1	
63	Romozosumab: Optimizing the Anabolic Window. 2022 , 593-616		0
62	Preclinical Pharmacokinetics and Dosimetry of an Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.. <i>Frontiers in Medicine</i> , 2021 , 8, 741855	4.9	
61	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	
60	Clinical Application of Monoclonal Antibodies: Key Technological Advances and Treatment of Osteoporosis. <i>Springer Series in Biomaterials Science and Engineering</i> , 2022 , 75-109	0.6	

59	Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. <i>British Journal of Clinical Pharmacology</i> , 2022 ,	3.8	
58	Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 821944	5.6	0
57	Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.. <i>Nanotheranostics</i> , 2022 , 6, 243-255	5.6	0
56	Population pharmacokinetics and exposure-response relationships of astegolimab in patients with severe asthma.. <i>Journal of Clinical Pharmacology</i> , 2021 ,	2.9	
55	.. <i>Drug Metabolism and Disposition</i> , 2022 ,	4	1
54	.. <i>Drug Metabolism and Disposition</i> , 2022 ,	4	0
53	Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. <i>Acta Pharmaceutica Sinica B</i> , 2022 ,	15.5	5
52	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 515	3.5	1
51	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	1
50	Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab.. <i>Journal of Clinical Pharmacology</i> , 2022 ,	2.9	0
49	Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid.. <i>Pharmaceutics</i> , 2021 , 13,	6.4	0
48	A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).. <i>Cancer Treatment Reviews</i> , 2022 , 106, 102393	14.4	1
47	Data_Sheet_1.pdf. 2019 ,		
46	Data_Sheet_1.docx. 2018 ,		
45	Lipid Nanoparticle Delivery of Unmodified mRNAs Encoding Multiple Monoclonal Antibodies Targeting Poxviruses in Rabbits. <i>Molecular Therapy - Nucleic Acids</i> , 2022 ,	10.7	2
44	Predicting Approximate Clinically Effective Doses in Oncology Using Preclinical Efficacy and Body Surface Area Conversion: A Retrospective Analysis.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 830972	5.6	
43	Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. <i>European Journal of Medical Research</i> , 2022 , 27,	4.8	2
42	Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab. <i>JAMA Dermatology</i> ,	5.1	0

41	Development of a Lateral Flow Assay for Bevacizumab Using an Anti-Idiotypic DNA Aptamer as a Capture Molecule. <i>Chromatography</i> , 2022 ,	1.2	0
40	Absorption of Biotechnology-Derived Biologics Drug Products. 2022 , 53-61		
39	Plasma Exchange for Severe Immune-Related Adverse Events from Checkpoint Inhibitors: An Early Window of Opportunity?. <i>Immunotherapy Advances</i> ,		1
38	Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022 , 37, 355-363	3.9	
37	Brain metabolic changes in patients with disseminated malignant melanoma under immunotherapy. <i>Melanoma Research</i> , Publish Ahead of Print,	3.3	0
36	Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> ,	3.2	
35	The manufacturing considerations of bispecific antibodies. <i>Expert Opinion on Biological Therapy</i> , 1-23	5.4	0
34	Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies. <i>MAbs</i> , 2022 , 14,	6.6	
33	Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis. 13,		
32	Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic. 2022 , 14,		0
31	Interpretation of Clinical Efficacy of Biologics in Chronic Rhinosinusitis With Nasal Polyps via Understanding the Local and Systemic Pathomechanisms. 2022 , 14, 465		0
30	Antibodies as Antibacterial Molecules: The New Era of Antibody-Mediated Immunity. 2022 , 83-108		0
29	Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration. 13,		0
28	Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation.		0
27	Monoclonal Antibodies. 2022 , 194-219		0
26	Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data. 1-5		0
25	Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections. 2022 , 10, 1789		0
24	Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.		1

23	Low-molecular weight inhibitors of the alternative complement pathway.	0
22	Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection. 2022 , 23, 12754	0
21	ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs). 1-44	0
20	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Efficacy and Safety in the Treatment of Hypercholesterolaemia. 88-97	0
19	A Non-radiometric Approach to Determine Tissue Vascular Blood Volume in Biodistribution Studies. 2022 , 24,	0
18	Non-specificity as the sticky problem in therapeutic antibody development.	5
17	Molecular prediction of clinical response to anti-PD -1/ anti-PD-L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry-based investigations.	0
16	Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper. 2022 , 14,	0
15	Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing. 2022 , 11, 7477	0
14	Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338).	0
13	Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. 2023 , 115, 109638	0
12	Half-Life Extension and Biodistribution Modulation of Biotherapeutics via Red Blood Cell Hitch-Hiking with Novel Anti-Band 3 Single-Domain Antibodies. 2023 , 24, 475	0
11	A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors. Volume 16, 29-36	0
10	Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. 2023 , 15, 713	2
9	A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies. 2023 , 15, 175883592311659	0
8	Relationship between Body Composition and Serum Immunoglobulin Concentrations after Administration of Intravenous Immune Globulin. Preclinical and Clinical Evidence. 2023 , 15, 510	0
7	Immunogenicity of Therapeutic Proteins. 2023 , 251-273	0
6	Neuropeptide Binding Autoantibodies Regulating Neuroendocrine Communications. 2023 , 187-204	0

- 5 Mechanisms of Obesity-Induced Changes in Pharmacokinetics of IgG in Rats. ○
- 4 Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics. **2023**, 15, ○
- 3 Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies. ○
- 2 A Novel Highly Sensitive Chemiluminescence Enzyme Immunoassay with Signal Enhancement Using Horseradish Peroxidase-Luminol-Hydrogen Peroxide Reaction for the Quantitation of Monoclonal Antibodies Used for Cancer Immunotherapy. **2023**, 11, 245 ○
- 1 Leveraging neural crest pluripotency to extend retinal and craniofacial niches for building neurovascular organoids: a theranostic and drug development perspective. **2023**, 55-118 ○